PF-06838435 (formerly SPK-9001)
Phase 2Biologic
PfizerPF-06838435 (formerly SPK-9001) is one of 20 biologic programs targeting Hemophilia B. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
42 competitors in Hemophilia B
#DrugCompanyPhaseTrials
1Recombinant Factor IX Coagulation
PfizerApproved
IB1001
MMedexus Pharma, Inc.
Phase 3
Translarna
PPTC Therapeutics
Phase 2
BENEFIX
PfizerPhase 3
Recombinant Factor IX
BBaxalta now part of Shire
Phase 3
Rfix
PfizerPhase 3
Factor Ix
CSL BehringPhase 3
Rix-FP
CSL BehringPhase 3
Nonacog Alfa
PfizerPhase 3
Rfixfc
BBioverativ Therapeutics Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]